October 19, 2026 (MLN): The Competition Commission of Pakistan (CCP) has approved the proposed acquisition of 100% shareholding of Pakheim International Pharma (Private) Limited by Citi Pharma Limited (PSX: CPHL), according to a filing submitted to the Pakistan Stock Exchange.
The CCP issued its order dated October 9, 2026, in Case No. 1614/Merger-CCP/2026, following a thorough review of the proposed transaction and its determination that the merger is not expected to raise competition concerns.
The acquisition will proceed under the terms of the Share Purchase Agreement dated May 6, 2026, and upon completion of all applicable legal, regulatory, and other necessary formalities.
Also Read
- Alberta rejects plan for referendum on independence from Canada
- UEFA Seeks Court Backing to Compel FIFA Document Disclosure Over World Cup Investment Plan
- Citi Research Highlights Aave’s Tokenization Potential as AAVE Navigates Technical Levels
- Pakistan’s Hajj payment deadline nears with 97,000 second installments recorded
